Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind placebo-controlled study of JNJ-53718678 in young children with RSV infection
jRCT2080224188Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of rilematovir in respiratory syncytial virus disease (RSV) and acute respiratory illness (ARI) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: AUC of RSV RNA viral load through Day 5. Started Dec 2018; status: completed.
02
Drugs
rilematovir
03
Conditions
respiratory syncytial virus disease (RSV)acute respiratory illness (ARI)
Beyond the preview
Go deeper on jRCT2080224188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224188.